C4 Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q3 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
C4 Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q3 2019 to Q3 2024.
  • C4 Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$24.7M, a 8.77% increase year-over-year.
  • C4 Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$105M, a 21.8% increase year-over-year.
  • C4 Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$132M, a 3.37% decline from 2022.
  • C4 Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$128M, a 52.8% decline from 2021.
  • C4 Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$83.9M, a 26.5% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$105M -$24.7M +$2.37M +8.77% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-31
Q2 2024 -$108M -$17.7M +$18.2M +50.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-10-31
Q1 2024 -$126M -$28.4M +$6.42M +18.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-10-31
Q4 2023 -$132M -$34.8M +$2.43M +6.54% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-22
Q3 2023 -$135M -$27M +$4.92M +15.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-31
Q2 2023 -$140M -$35.9M -$8.51M -31% Apr 1, 2023 Jun 30, 2023 10-Q 2024-10-31
Q1 2023 -$131M -$34.8M -$3.16M -9.99% Jan 1, 2023 Mar 31, 2023 10-Q 2024-10-31
Q4 2022 -$128M -$37.2M -$21.5M -137% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-22
Q3 2022 -$107M -$32M -$7.28M -29.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-01
Q2 2022 -$99.4M -$27.4M -$4.83M -21.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-01
Q1 2022 -$94.5M -$31.6M -$10.6M -50.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-01
Q4 2021 -$83.9M -$15.7M +$6.14M +28.2% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-23
Q3 2021 -$90M -$24.7M -$2.85M -13% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$87.2M -$22.6M -$11.8M -109% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-03
Q1 2021 -$75.4M -$21M -$9.06M -76% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-03
Q4 2020 -$66.3M -$21.8M Oct 1, 2020 Dec 31, 2020 10-K 2022-02-24
Q3 2020 -$21.8M -$11.7M -116% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$10.8M Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-10
Q1 2020 -$11.9M Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-10
Q3 2019 -$10.1M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.